The reclassifications have the potential to alter therapy decisions for patients following prostatectomy, by predicting whether an individual is at low, intermediate, or high risk of tumor metastasis.
Read More
Improvements in liquid biopsy techniques are offering a more holistic view of cancer.
Read MoreExperts have pointed out flaws in a recent study that received significant coverage in the lay media because of its implication of a “skyrocketing” increase in the incidence of metastatic prostate cancer.
Read More
This month’s Product Spotlight features molecular diagnostics technologies from such companies as Bio-Rad Laboratories, BioFire Diagnostics, Randox Laboratories, and Vela Diagnostics.
Read MoreMeasuring serum autoantibodies in a liquid biopsy of prostate cancer patients, researchers successfully confirmed tissue-specific biomarkers via immunohistochemistry.
Read More